Table 4.
Performance Characteristics for Algorithms in the VA Setting
| Variable | Sample Size (No.) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|
| ICD-9 code 416.0 or ICD-10 code I27.0 | 12,012 | —c | —c | 16.0 | —c |
| ICD PH codes plus RHC | 3,116 | 84.0 | 80.0 | 30.0 | 96.0 |
| ICD PH codes plus PAH-associated conditiona | 1,837 | 68.4 | 91.1 | 48.0 | 96.0 |
| ICD PH codes plus PAH-associated conditiona plus RHC | 690 | 44.2 | 97.0 | 52.0 | 96.0 |
| ICD PH codes plus PAH-specific therapyb | 2,151 | 86.4 | 91.5 | 58.0 | 98.0 |
| ICD PH codes plus RHC plus PAH-specific therapyb | 1,081 | 77.6 | 97.1 | 70.0 | 98.0 |
ICD = International Classification of Diseases; ICD-9 = International Classification of Diseases, Ninth Revision; ICD-10 = International Classification of Diseases, Tenth Revision; NPV = negative predictive value; PAH = pulmonary arterial hypertension; PPV = positive predictive value; RHC = right heart catheterization; VA = Veterans Health Administration.
Including connective tissue diseases, congenital heart disease, HIV infection, and portal hypertension.
Including prostacyclin, prostacyclin receptor agonist, endothelin receptor antagonist, phosphodiesterase-5-inhibitor, or soluble guanylate cyclase agonist.
Sensitivity, specificity, and NPV could not be calculated as this is the reference group for the other algorithms.